Logo image of ATXS

ASTRIA THERAPEUTICS INC (ATXS) Stock Fundamental Analysis

NASDAQ:ATXS - Nasdaq - US04635X1028 - Common Stock - Currency: USD

6.19  -0.23 (-3.58%)

After market: 6.19 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ATXS. ATXS was compared to 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ATXS as it has an excellent financial health rating, but there are worries on the profitability. ATXS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ATXS had negative earnings in the past year.
ATXS had a negative operating cash flow in the past year.
ATXS had negative earnings in each of the past 5 years.
In the past 5 years ATXS always reported negative operating cash flow.
ATXS Yearly Net Income VS EBIT VS OCF VS FCFATXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

ATXS's Return On Assets of -27.66% is fine compared to the rest of the industry. ATXS outperforms 70.16% of its industry peers.
ATXS has a Return On Equity of -29.28%. This is in the better half of the industry: ATXS outperforms 78.53% of its industry peers.
Industry RankSector Rank
ROA -27.66%
ROE -29.28%
ROIC N/A
ROA(3y)-74.38%
ROA(5y)-72.91%
ROE(3y)-77.59%
ROE(5y)-79.61%
ROIC(3y)N/A
ROIC(5y)N/A
ATXS Yearly ROA, ROE, ROICATXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200

1.3 Margins

ATXS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATXS Yearly Profit, Operating, Gross MarginsATXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K -4K -5K

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for ATXS has been increased compared to 1 year ago.
Compared to 5 years ago, ATXS has more shares outstanding
ATXS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ATXS Yearly Shares OutstandingATXS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
ATXS Yearly Total Debt VS Total AssetsATXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

ATXS has an Altman-Z score of 8.03. This indicates that ATXS is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 8.03, ATXS belongs to the top of the industry, outperforming 85.69% of the companies in the same industry.
There is no outstanding debt for ATXS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.03
ROIC/WACCN/A
WACCN/A
ATXS Yearly LT Debt VS Equity VS FCFATXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

ATXS has a Current Ratio of 22.38. This indicates that ATXS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 22.38, ATXS belongs to the top of the industry, outperforming 96.16% of the companies in the same industry.
A Quick Ratio of 22.38 indicates that ATXS has no problem at all paying its short term obligations.
ATXS has a Quick ratio of 22.38. This is amongst the best in the industry. ATXS outperforms 96.16% of its industry peers.
Industry RankSector Rank
Current Ratio 22.38
Quick Ratio 22.38
ATXS Yearly Current Assets VS Current LiabilitesATXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

ATXS shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.36%.
EPS 1Y (TTM)1.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ATXS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.81% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y28.56%
EPS Next 2Y10.85%
EPS Next 3Y6.03%
EPS Next 5Y11.81%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ATXS Yearly Revenue VS EstimatesATXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
ATXS Yearly EPS VS EstimatesATXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -50 -100 -150 -200

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ATXS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ATXS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATXS Price Earnings VS Forward Price EarningsATXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATXS Per share dataATXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.85%
EPS Next 3Y6.03%

More info and screens

0

5. Dividend

5.1 Amount

ATXS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASTRIA THERAPEUTICS INC

NASDAQ:ATXS (3/7/2025, 8:06:07 PM)

After market: 6.19 0 (0%)

6.19

-0.23 (-3.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)05-07 2025-05-07/amc
Inst Owners92.9%
Inst Owner Change5.25%
Ins Owners0.47%
Ins Owner Change0%
Market Cap349.30M
Analysts85.71
Price Target27.03 (336.67%)
Short Float %6.19%
Short Ratio10.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.58%
Min EPS beat(2)-9.5%
Max EPS beat(2)2.33%
EPS beat(4)1
Avg EPS beat(4)-6.91%
Min EPS beat(4)-18.12%
Max EPS beat(4)2.33%
EPS beat(8)4
Avg EPS beat(8)-1.94%
EPS beat(12)6
Avg EPS beat(12)-132.03%
EPS beat(16)8
Avg EPS beat(16)-99.98%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.27%
PT rev (3m)5.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.11%
EPS NY rev (1m)0.13%
EPS NY rev (3m)0.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.02
P/tB 1.02
EV/EBITDA N/A
EPS(TTM)-2.17
EYN/A
EPS(NY)-1.87
Fwd EYN/A
FCF(TTM)-1.67
FCFYN/A
OCF(TTM)-1.67
OCFYN/A
SpS0
BVpS6.05
TBVpS6.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.66%
ROE -29.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-74.38%
ROA(5y)-72.91%
ROE(3y)-77.59%
ROE(5y)-79.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.38
Quick Ratio 22.38
Altman-Z 8.03
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y28.56%
EPS Next 2Y10.85%
EPS Next 3Y6.03%
EPS Next 5Y11.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-84.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-42.06%
EBIT Next 3Y-20.75%
EBIT Next 5Y-14.4%
FCF growth 1Y-140.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-140.32%
OCF growth 3YN/A
OCF growth 5YN/A